Theralase Announces Breakthrough Scientific Research



    TORONTO, Oct. 7 /CNW/ - Theralase(R) Technologies Inc. (TSX-V: TLT) today
announced the completion of independent scientific research performed at
University Health Network demonstrating that Theralase's(R) proprietary
super-pulsed 905 nanometer (nm) laser technology produces significantly more
nitric oxide as compared to other tested laser sources.
    Nitric oxide production has been previously demonstrated in published
clinical studies to increase the diameter of capillaries, bringing much needed
oxygen and fuel molecules to injured tissue, accelerating their natural
healing processes, as well as activating and controlling inflammation. The
high effect of the Theralase(R) super-pulsed 905 nm laser technology has been
scientifically demonstrated to be due to laser-tissue interactions which can
not be attained by non-super-pulsed techniques.
    "We are pleased to demonstrate what our customers have always known, that
the Theralase(R) proprietary 905 nm super-pulsed technology has created the
best therapeutic laser on the market," said Roger Dumoulin-White, President &
CEO of Theralase(R) Technologies. "Our technology has been scientifically
proven to activate both known cellular pathways: the ATP pathway, which
increases the energy to cells, and the Nitric Oxide pathway, which increases
the blood flow to cells, while also reducing inflammation. By activating both
known cellular pathways, the Theralase(R) proprietary 905 nm super-pulsed
technology has now been proven to be more effective in neural muscular
skeletal conditions, wound healing and chronic pain as compared to competitive
systems."

    Theralase Technologies Inc. designs, develops and manufactures patented,
super-pulsed laser technology used in a wide range of bio-stimulation and
bio-destruction clinical applications. The Theralase technology platform
targets several diverse healthcare sectors: firstly, for non-invasive pain
management and clinical therapy, in hundreds of neural muscular skeletal
conditions including arthritis; secondly, to bio-stimulate and accelerate
wound care and healing including bone fracture regeneration; and thirdly,
combining photodynamic compounds with super-pulsed, biofeedback laser
technology to attack specifically targeted cancer, bacteria, viruses and fat
cells.

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the contents of this
    release.
    





For further information:

For further information: Roger White, President & CEO, Toll Free:
1-866-THE-LASE (843-5273), Phone: (416) 447-8455, e-mail:
rwhite@theralase.com; Vanessa Beresford, The Equicom Group, Phone: (416)
815-0700 ext 227, e-mail: vberesford@equicomgroup.com

Organization Profile

THERALASE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890